Chief Financial Officer · Sagimet Biosciences Inc. (SGMT)

Thierry Chauche

FY2024 is the first fiscal year CompBrief holds for Thierry Chauche as a named executive officer of Sagimet Biosciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,407,476

Salary $314,545Stock awards $0

1st of 4 named executive officers at Sagimet Biosciences by FY2024 total.

4 named officers on file for Sagimet Biosciences, FY2024

Thierry Chauche’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Sagimet Biosciences’s whole pay program stands against its peers

  • Sagimet Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SGMT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A).

Free

Get Thierry Chauche’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Thierry Chauche compensation by year

Sagimet Biosciences Summary Compensation Table · the one fiscal year held
In US dollars, as Sagimet Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$314,545
Bonus$0
Stock awards$0
Option awards$1,966,704
Non-equity incentive$125,721
Pension and deferred compensation$0
All other$506
Total$2,407,476

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sagimet Biosciences Inc. DEF 14A filed April 30, 2025, accession 0001104659-25-042560, and prior-year filings.

How this page was built: the Sagimet Biosciences Inc. filed document, accession 0001104659-25-042560. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option587,181—$4.28

Per the Outstanding Equity Awards at Fiscal Year-End table in Sagimet Biosciences Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Sagimet Biosciences’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Thierry Chauche · this pageChief Financial Officer$2,407,476
David HappelPresident and Chief Executive Officer$906,164
Eduardo MartinsChief Medical Officer$669,064
Elizabeth RozekChief Legal and Administrative Officer$626,142

The full Sagimet Biosciences compensation record

free company brief

This page is one person within Sagimet Biosciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sagimet Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thierry Chauche's compensation dossier · One-time report. No refunds.